H. Lundbeck A/S- (OTCMKTS:HLUYY) Upgraded to Hold at Zacks Investment Research

H. Lundbeck A/S- (OTCMKTS:HLUYY) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Friday, Zacks.com reports.

According to Zacks, “H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of pharmaceuticals across the world. Its products are targeted at disorders like depression and anxiety, schizophrenia, insomnia, Huntington’s, epilepsies, Alzheimer’s and Parkinson’s diseases. The Company is involved in the development of new and improved drugs for the treatment of psychiatric and neurological disorders. H. Lundbeck A/S is headquartered in Copenhagen, Denmark. “

Separately, ValuEngine upgraded shares of H. Lundbeck A/S- from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the company’s stock. H. Lundbeck A/S- currently has a consensus rating of “Hold” and an average price target of $53.00.

OTCMKTS:HLUYY traded down $0.81 during mid-day trading on Friday, hitting $34.94. The stock had a trading volume of 5,000 shares, compared to its average volume of 4,353. H. Lundbeck A/S- has a twelve month low of $34.34 and a twelve month high of $64.20. The stock has a market cap of $6.95 billion, a price-to-earnings ratio of 9.29, a PEG ratio of 8.35 and a beta of 0.02. The company’s 50 day simple moving average is $37.80 and its 200 day simple moving average is $40.76. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.08 and a current ratio of 1.32.

About H. Lundbeck A/S-

H. Lundbeck A/S engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for treating symptomatic neurogenic orthostatic hypotension; Onfi for Lennox-Gastaut syndrome; and Rexulti to treat depression/schizophrenia.

Read More: What are no-load funds?

Get a free copy of the Zacks research report on H. Lundbeck A/S- (HLUYY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for H. Lundbeck A/S- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H. Lundbeck A/S- and related companies with MarketBeat.com's FREE daily email newsletter.